Nullscript inhibits Cryptosporidium and Toxoplasma growth

Fumi Murakoshi, Hironori Bando, Tatsuki Sugi, Oluyomi Stephen Adeyemi, Motohiro Nonaka, Takaaki Nakaya, Kentaro Kato

Research output: Contribution to journalArticlepeer-review

Abstract

Cryptosporidium and Toxoplasma are parasites that have caused problems worldwide. Cryptosporidium causes severe watery diarrhoea and may be fatal in immunocompromised patients and in infants. Nitazoxanide is the only agent currently approved by the FDA, but its efficacy is limited. Toxoplasmosis is also a problem in the immunocompromised, as currently available treatment options have limited efficacy and patient tolerance can be poor. In the present investigation, we screened libraries of epigenetic compounds to identify those that inhibited C. parvum growth. Nullscript was identified as a compound with an inhibitory effect on C. parvum and T. gondii growth, and was less toxic to host cells. Nullscript was also able to significantly decrease oocyst excretion in C. parvum-infected SCID mice.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalInternational Journal for Parasitology: Drugs and Drug Resistance
Volume14
DOIs
Publication statusPublished - 2020 Dec

Keywords

  • Cryptosporidium
  • HDAC inhibitor
  • Nullscript
  • Toxoplasma

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Nullscript inhibits Cryptosporidium and Toxoplasma growth'. Together they form a unique fingerprint.

Cite this